首页> Acta biomaterialia> Arg-Gly-Asp engineered mesenchymal stem cells as targeted nanotherapeutics against kidney fibrosis by modulating m6A.

Arg-Gly-Asp engineered mesenchymal stem cells as targeted nanotherapeutics against kidney fibrosis by modulating m6A.

导出 LinkOut

翻译打印收藏纠错

第一作者： Xin,Zhang

第一单位： Department of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China; Clinical Research Center For Kidney Disease, Xuzhou Medical University, Xuzhou, China; Department of Internal Medicine and Diagnostics, Xuzhou Medical University, Xuzhou, China.

作者： Xin,Zhang ^[1] ; Jiaqi,Zhao ^[1] ; Rui,Ge ^[1] ; Xiangyu,Zhang ^[2] ; Haihan,Sun ^[3] ; Yuhan,Guo ^[1] ; Yanping,Wang ^[1] ; Lu,Chen ^[4] ; Shulin,Li ^[1] ; Jing,Yang ^[3] ; Dong,Sun ^[5]

作者单位： Department of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China; Clinical Research Center For Kidney Disease, Xuzhou Medical University, Xuzhou, China; Department of Internal Medicine and Diagnostics, Xuzhou Medical University, Xuzhou, China. ^[1] Department of Nephrology, Ningbo City first Hospital, Ningbo, China. ^[2] Department of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China; Clinical Research Center For Kidney Disease, Xuzhou Medical University, Xuzhou, China. ^[3] Department of Rheumatology, Ningbo Medical Treatment Center Li Huili Hospital, Ningbo, China. ^[4] Department of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China; Clinical Research Center For Kidney Disease, Xuzhou Medical University, Xuzhou, China; Department of Internal Medicine and Diagnostics, Xuzhou Medical University, Xuzhou, China. Electronic address: sundong@xzhmu.edu.cn. ^[5]

关键词 EV RGD peptide Renal interstitial fibrosis SIRT1 m6A